# A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

> **NCT04819100** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 152 (estimated)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Selpercatinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04819100
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-20
- **Primary completion:** 2026-01-12
- **Final completion:** 2028-05
- **Target enrollment:** 152 (ESTIMATED)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04819100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04819100, "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04819100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*